Feb 25 (Reuters) - ESSA Pharma Inc EPIX.O :
* ESSA PHARMA ANNOUNCES CLINICAL COLLABORATION WITH ASTELLAS TO EVALUATE THE COMBINATION OF EPI-7386 AND ENZALUTAMIDE FOR PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
* ESSA PHARMA- CO TO SPONSOR & CONDUCT PHASE 1/2 STUDY TO EVALUATE SAFETY, TOLERABILITY & PRELIMINARY EFFICACY OF COMBINATION OF EPI-7386 & ENZALUTAMIDE
* ESSA PHARMA - PHASE 1/2 STUDY TO BE COMNDUCTED IN MCRPC PATIENTS WHO HAVE NOT YET BEEN TREATED WITH SECOND-GENERATION ANTIANDROGEN THERAPIES
* ESSA PHARMA INC - ASTELLAS WILL SUPPLY ENZALUTAMIDE FOR TRIAL
* ESSA PHARMA INC - ESSA WILL RETAIN ALL RIGHTS TO EPI-7386
* ESSA PHARMA INC - PHASE 1/2 STUDY FOR COMBINATION OF EPI-7386 & ENZALUTAMIDE EXPECTED TO START IN 2021